FDA Orange Book vs. Biologic PTAB: The Data-Driven Patent Strategy Guide Pharma Can’t Ignore
The gap between how small-molecule and biologic patents perform at the Patent Trial and Appeal Board has never been wider, […]
Pay-for-Delay Pharma Settlements: The Complete Antitrust & IP Strategy Guide
Pharmaceutical pay-for-delay agreements, the precise term is reverse payment patent settlements, sit at the intersection of Hatch-Waxman exclusivity mechanics, branded
Pay-for-Delay Pharma Settlements: The Complete Antitrust & IP Strategy Guide Read Post »
Authorized Generics: The Brand’s Last Weapon Against Generic Entry (And What It Costs Everyone Else)
Section 1: What an Authorized Generic Actually Is (And Why Definitions Matter for Deal Modeling) 1.1 The Core Definition An
DrugPatentWatch reveals NIH funding for patents
Here’s a summary of a new article that used DrugPatentWatch data: NIH Funding for Patents That Contribute to Market Exclusivity
DrugPatentWatch reveals NIH funding for patents Read Post »
Pharma Patent Filing Strategies That Maximize Exclusivity: The Complete IP Playbook
For IP teams, portfolio managers, R&D leads, and institutional investors who need more than an overview. A pharmaceutical patent is
Pharma Patent Filing Strategies That Maximize Exclusivity: The Complete IP Playbook Read Post »
NPR and DrugPatentWatch – Can drug injector pens be swapped?
On NPR’s All Things Considered, Sydney Lupkin asked DrugPatentWatch if drug patents could be used to identify injector pens which
NPR and DrugPatentWatch – Can drug injector pens be swapped? Read Post »
The 505(b)(2) Playbook: Cut Dev Time, Lock In Exclusivity, and Outmaneuver Generics
1. Why the 505(b)(2) Pathway Exists and Who It Rewards The Hatch-Waxman Design Intent The Drug Price Competition and Patent
The 505(b)(2) Playbook: Cut Dev Time, Lock In Exclusivity, and Outmaneuver Generics Read Post »
DrugPatentWatch named “Best of the Web” by Genetic Engineering News
DrugPatentWatch has been named to Genetic Engineering News‘ Best of the Web list. The review by Genetic Engineering News profile
DrugPatentWatch named “Best of the Web” by Genetic Engineering News Read Post »
Sell the use, not the molecule
The innovation-exclusivity-reinvestment cycle The fundamental economic engine of the innovator pharmaceutical industry functions through a self-sustaining loop. This cycle begins
Sell the use, not the molecule Read Post »
